DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists

Podobne zapisy

• Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
  od: Hernández-Cruz, Blanca, i wsp.
  Wydane: (2016)
• Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
  od: Hyrich, K. L., i wsp.
  Wydane: (2008)
• Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
  od: Gomez-Reino, Juan J, i wsp.
  Wydane: (2006)
• All‐cause and cause‐specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists
  od: Carmona, Loreto, i wsp.
  Wydane: (2007)
• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature
  od: M. Di Franco, i wsp.
  Wydane: (2011-06-01)